-
04:55:10 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

SNOA Stock News

06/01/22 6:00 AM
Nasdaq : SNOA
covid-19low float
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that...
RHEA-AI
positive
05/03/22 6:00 AM
Nasdaq : SNOA
low float
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for...
RHEA-AI
very positive
03/30/22 6:00 AM
Nasdaq : SNOA
low float
Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox ®, an urinary tract infection catheter and...
RHEA-AI
neutral
01/20/22 4:40 PM
Nasdaq : SNOA
low float
Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional...
RHEA-AI
very positive
01/05/22 4:55 PM
Nasdaq : SNOA
conferenceslow float
Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.
RHEA-AI
neutral
11/09/21 7:00 AM
Nasdaq : SNOA
partnershiplow float
Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its long-time partner, Dyamed Biotech Pte Ltd., announce a renewed and expanded long-term...
RHEA-AI
very positive
10/15/21 7:00 AM
Nasdaq : SNOA
covid-19low float
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration...
RHEA-AI
neutral
09/28/21 7:00 AM
Nasdaq : SNOA
low float
Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter consumer launch of Regenacyn ® Advanced Scar Gel and Ocucyn ® Eyelid& Eyelash...
RHEA-AI
positive